Engineered immune cells injected into brain fluid show promise against deadly glioblastoma

NCT ID NCT05366179

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 25 times

Summary

This early-phase study tests the safety of a new treatment for glioblastoma, an aggressive brain cancer that has returned or not responded to standard therapy. The treatment involves taking a patient's own immune cells (T cells), modifying them in a lab to recognize and attack cancer cells, and then infusing them directly into the fluid around the brain. The study will enroll 36 adults and primarily aims to identify side effects and the best dose, not to cure the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Lineberger Comprehensive Cancer Center

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.